-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In acute myeloid leukemia (AML), there is ongoing debate about the prognostic value of early bone marrow (BM) assessment for patients receiving intensive treatment
In acute myeloid leukemia (AML), there is ongoing debate about the prognostic value of early bone marrow (BM) assessment for patients receiving intensive treatment
A study was conducted in a large number of intensively treated AML patients (n=1008) to analyze the prognostic effects of early explosive clearance on OS, EFS, and RFS, and to evaluate the long-term prognosis of patients with persistent early explosives
A study was conducted in a large number of intensively treated AML patients (n=1008) to analyze the prognostic effects of early explosive clearance on OS, EFS, and RFS, and to evaluate the long-term prognosis of patients with persistent early explosives
In the entire cohort and the three "remission groups" (early explosive clearance, early PR, and early drug-resistant AML), the distribution of baseline characteristics is shown in Table 1
Table 1: Baseline characteristics and treatment methods of the remission status of 1008 AML patients at the mid-term bone marrow assessment
Figure 1: Further treatment of 436 AML patients with persistent early explosions
Figure 1: Further treatment of 436 AML patients with persistent early explosions Figure 1: Further treatment of 436 AML patients with persistent early explosions Figure 1: Further treatment of 436 AML patients with persistent early explosionsThe research team found that early explosion persistence has independent negative prognostic effects on overall survival (OS), event-free survival (EFS) and recurrence-free survival (RFS)
The research team found that early explosion persistence has independent negative prognostic effects on overall survival (OS), event-free survival (EFS) and recurrence-free survival (RFS)
Table 2: For the entire cohort and patients in combined remission before combination therapy, the impact of early explosive persistence on survival Table 2: For the entire cohort and patients in combined remission before combined therapy, the impact of early explosive persistence on survival
If the response is obtained before the treatment after induction, the negative prognostic impact of the persistence of the early explosion can be overcome
If the response is obtained before the treatment after induction, the negative prognostic impact of the persistence of the early explosion can be overcome
In addition, in the etiology-specific risk model that included the same covariates, patients with early burst persistence showed an increased risk of recurrence (CS-HR1.
Interestingly, in the group where the early explosion persists, the survival rate is very heterogeneous, depending on whether the patient has at least early PR or exhibits early drug-resistant disease (Figure 2)
Figure 3: The overall cohort's OS and RFS after combined remission before post-induction treatment (before allogeneic HSCT or before consolidation chemotherapy), and the early remission status at the mid-term BM assessment
They suggest that the time slope of remission is an additional leukemia-related dynamic parameter, which reflects chemosensitivity and therefore can provide information for treatment decisions after induction
They suggest that the time slope of remission is an additional leukemia-related dynamic parameter, which reflects chemosensitivity and therefore can provide information for treatment decisions after induction
Original source:
Leave a message here
